LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.

Pilar Garrido LopezLuis Paz-AresMargarita MajemTeresa MoránJosé Manuel TrigoJoaquim Bosch-BarreraRosario Garcίa-CampeloJosé Luis González-LarribaJosé Miguel Sánchez-TorresDolores IslaNúria ViñolasCarlos CampsAmelia InsaÓscar JuanBartomeu MassutiAlfredo ParedesÁngel ArtalMarta López-BreaJosé PalaciosEnriqueta Felip

Published in: Cancer medicine (2021)

Detection and quantification of EGFR mutations in circulating tumor DNA using the highly sensitive BEAMing method should greatly assist in optimizing treatment decisions for advanced NSCLC patients.

Keyphrases

small cell lung cancer
circulating tumor
cell free
epidermal growth factor receptor
end stage renal disease
newly diagnosed
tyrosine kinase
ejection fraction
advanced non small cell lung cancer
peritoneal dialysis
prognostic factors
patient reported outcomes
high resolution
molecularly imprinted
patient reported